These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 18393001)

  • 21. [Isolated hyperthermic antiblastic perfusion in recurrent melanoma of the extremities].
    De Cian F; Rainero ML; Mondini G; Spirito C; D'Addazio G; Simoni GA; Civalleri D
    Minerva Chir; 1994; 49(7-8):681-91. PubMed ID: 7991176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response.
    Aloia TA; Grubbs E; Onaitis M; Mosca PJ; Cheng TY; Seigler H; Tyler DS
    Arch Surg; 2005 Nov; 140(11):1115-20. PubMed ID: 16301451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Current aspects in the treatment of malignant melanoma].
    Barth A; Cerny T
    Schweiz Med Wochenschr; 1994 Sep; 124(36):1592-603. PubMed ID: 7939527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma.
    Möller MG; Lewis JM; Dessureault S; Zager JS
    Int J Hyperthermia; 2008 May; 24(3):275-89. PubMed ID: 18393005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities.
    Taeger G; Grabellus F; Podleska LE; Müller S; Ruchholtz S
    Int J Hyperthermia; 2008 May; 24(3):193-203. PubMed ID: 18392998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
    Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS
    J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Future directions in regional treatment strategies for melanoma and sarcoma.
    Beasley GM; Ross MI; Tyler DS
    Int J Hyperthermia; 2008 May; 24(3):301-9. PubMed ID: 18393007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and clinical status of 41.8 degrees C systemic hyperthermia tumor necrosis factor, and melphalan for neoplastic disease.
    Robins HI; D'Oleire F; Grosen E; Spriggs D
    Anticancer Res; 1997; 17(4B):2891-4. PubMed ID: 9329556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isolated limb perfusion: what is the evidence for its use?
    Noorda EM; Vrouenraets BC; Nieweg OE; Van Coevorden F; Kroon BB
    Ann Surg Oncol; 2004 Sep; 11(9):837-45. PubMed ID: 15313738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILI.
    Padussis JC; Steerman SN; Tyler DS; Mosca PJ
    Int J Hyperthermia; 2008 May; 24(3):239-49. PubMed ID: 18393002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term response of isolated limb perfusion with hyperthermia and chemotherapy for Merkel cell carcinoma.
    Duprat JP; Domingues AL; Coelho EG; Leal RM; Nishinari K; Neves RI
    Eur J Surg Oncol; 2009 Jun; 35(6):568-72. PubMed ID: 19013049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolated limb perfusion in regional melanoma.
    Noorda EM; Vrouenraets BC; Nieweg OE; Kroon BB
    Surg Oncol Clin N Am; 2006 Apr; 15(2):373-84. PubMed ID: 16632221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
    Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
    J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternatives for the treatment of local advanced disease: electrochemotherapy, limb perfusion, limb infusion, intralesional IL2. What is the role?
    Testori A; Intelisano A; Verrecchia F; Menicanti C; Tosti G; Grassi E; Pari C; Pennacchioli E
    Dermatol Ther; 2012; 25(5):443-51. PubMed ID: 23046023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma.
    Kroon HM; Lin DY; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1193-201. PubMed ID: 19224288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The past decade of experience with isolated hepatic perfusion.
    Grover A; Alexander HR
    Oncologist; 2004; 9(6):653-64. PubMed ID: 15561809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isolated limb perfusion for melanoma.
    Kroon BB; Noorda EM; Vrouenraets BC; Nieweg OE
    J Surg Oncol; 2002 Apr; 79(4):252-5. PubMed ID: 11920783
    [No Abstract]   [Full Text] [Related]  

  • 39. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.
    Lejeune FJ; Eggermont AM
    J Clin Oncol; 2007 Apr; 25(11):1449-50; author reply 1450-1. PubMed ID: 17416870
    [No Abstract]   [Full Text] [Related]  

  • 40. Isolated limb perfusion for malignant melanoma; possibly better results with high dose hyperthermia.
    Van der Zee J; Kroon BB
    Int J Hyperthermia; 2008 Nov; 24(7):602-3; author reply 604. PubMed ID: 18979311
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.